SCHEDULE: State Street Discloses 5.1% Stake in Celldex Therapeutics

State Street Corporation has reported a 5.1% beneficial ownership stake in Celldex Therapeutics Inc., holding 3,397,713 shares of common stock as of December 31, 2025.

Summary

• State Street Corporation, a parent holding company, reported beneficial ownership of 3,397,713 shares of Celldex Therapeutics Inc. common stock.
• This ownership represents 5.1% of the class of securities.
• State Street Corporation holds shared voting power over 3,194,178 shares and shared dispositive power over 3,397,713 shares.
• The shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Subsidiaries involved in the beneficial ownership include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd., all classified as Investment Advisers.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of beneficial ownership by a large institutional investor and does not contain new operational or financial information about the issuer.

Positives

• A major institutional investor, State Street Corporation, maintains a significant 5.1% stake in Celldex Therapeutics, indicating continued institutional interest.
• The filing confirms the shares are held in the ordinary course of business, not for activist purposes, suggesting a passive investment.

Industry Context

StockSavvy.ai notes that institutional ownership disclosures like this Schedule 13G are common for large asset managers such as State Street Corporation, which manage vast portfolios across numerous public companies. A 5.1% stake in Celldex Therapeutics indicates that the company remains a component of State Street's managed funds, aligning with broader trends of institutional investment in the biotechnology sector.

Comparison to Industry Standards

• Institutional ownership by major asset managers like State Street is a standard practice across global markets, with similar disclosures made by BlackRock, Vanguard, and Fidelity for their holdings in various companies, including peers of Celldex Therapeutics in the biotech space.
• A 5.1% stake is above the 5% threshold for Schedule 13G filings, which is a common reporting benchmark for significant beneficial ownership across U.S. public companies.

Stakeholder Impact

• Shareholders: The continued significant institutional ownership by State Street may be viewed positively, suggesting confidence from a major investor.
• Management: Awareness of a large, passive institutional holder.

Key Dates

Keywords

Celldex Therapeutics, State Street Corporation, CDLX, Institutional Ownership, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Advisor, Biotechnology